328 Stock Overview
A clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
MeiraGTx Holdings plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.44 |
| 52 Week High | US$7.35 |
| 52 Week Low | US$3.40 |
| Beta | 1.31 |
| 1 Month Change | -3.90% |
| 3 Month Change | -29.52% |
| 1 Year Change | -13.79% |
| 3 Year Change | -44.15% |
| 5 Year Change | -67.11% |
| Change since IPO | -71.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| 328 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.7% | -0.3% | 0.8% |
| 1Y | -13.8% | -12.7% | 14.6% |
Return vs Industry: 328 underperformed the German Biotechs industry which returned -12.3% over the past year.
Return vs Market: 328 underperformed the German Market which returned 14.6% over the past year.
Price Volatility
| 328 volatility | |
|---|---|
| 328 Average Weekly Movement | 13.8% |
| Biotechs Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 328's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 328's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 372 | Alexandria Forbes | meiragtx.com |
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren’s syndrome; AAV-GAD in Phase 2 trial for Parkinson’s disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4.
MeiraGTx Holdings plc Fundamentals Summary
| 328 fundamental statistics | |
|---|---|
| Market cap | €359.68m |
| Earnings (TTM) | -€150.08m |
| Revenue (TTM) | €30.95m |
11.6x
P/S Ratio-2.4x
P/E RatioIs 328 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 328 income statement (TTM) | |
|---|---|
| Revenue | US$34.51m |
| Cost of Revenue | US$25.17m |
| Gross Profit | US$9.34m |
| Other Expenses | US$176.67m |
| Earnings | -US$167.33m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.08 |
| Gross Margin | 27.06% |
| Net Profit Margin | -484.90% |
| Debt/Equity Ratio | 222.0% |
How did 328 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/18 09:14 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MeiraGTx Holdings plc is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Alec Stranahan | BofA Global Research |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |